Elsevier

Vaccine

Volume 14, Issues 17–18, December 1996, Pages 1620-1626
Vaccine

Paper
Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults

https://doi.org/10.1016/S0264-410X(96)00146-6Get rights and content

Abstract

The safety, reactogenicity and immunogenicity of three candidate Lyme vaccines based on recombinant outer surface protein (OspA) presented in either lipidated or unlipidated forms, were assessed in 300 seronegative volunteers. Subjects received three doses of one of the three formulations at monthly intervals and were evaluated for antibody levels and the presence of symptoms after each dose. All formulations proved to be safe, the majority of local reactions being reported as mild, and all general symptoms were perceived to be either mild or moderate in intensity. No subject refused a subsequent vaccine dose. All subjects were tested for both anti-OspA IgG and LA-2 equivalent antibodies up until day 84. All three vaccines induced an immune response, but subjects who received lipoprotein OspA had the highest anti-OspA IgG and LA-2 equivalent GMTs after each dose and this was also true for the subset of subjects tested on day 180. The lipoprotein OspA group also had the largest number of subjects who remained seropositive for anti-OspA IgG antibodies. As the lipoprotein formulation produced the strongest immune response, with symptoms which were acceptable to all the vaccinees, we suggest further development of this vaccine.

References (18)

There are more references available in the full text version of this article.

Cited by (61)

  • Lyme Disease Vaccines

    2017, Plotkin's Vaccines
  • A Short History of Vaccination

    2017, Plotkin's Vaccines
  • Technologies for Making New Vaccines

    2017, Plotkin's Vaccines
  • Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: A double-blind, randomised, dose-escalation phase 1/2 trial

    2013, The Lancet Infectious Diseases
    Citation Excerpt :

    With respect to the inverse dose response after the booster immunisation, a reduced antigen dose might be sufficient to induce substantial antibody titres. However, in previous studies of a monovalent OspA-1 vaccine, substantially higher antibody titres were reported for a 30 μg adjuvanted dose24 than for a 10 μg adjuvanted dose.25 The safety and immunogenicity of monovalent OspA-1 vaccines formulated with or without adjuvant have been investigated in several previous studies.9,10,24,26–29

  • A short history of vaccination

    2012, Vaccines: Sixth Edition
  • Technologies for making new vaccines

    2012, Vaccines: Sixth Edition
View all citing articles on Scopus
View full text